ClinicalTrials.gg
Sign In
RecruitingNCT05390424BUVARD76_27Updated Feb 17, 2026

Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot

An interventional study of Blood collection using Dried Blood Spot in Hepatitis B, Hepatitis C and AIDS, sponsored by University Hospital, Rouen. Recruiting at 11 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to screen for hepatitis B, hepatitis C and AIDS viruses using a Dried Blood Spot in drug users

02

Conditions studied

  • Hepatitis B
  • Hepatitis C
  • AIDS

Keywords

  • Dried Blood Spot
03

In context

Hepatitis B

1,045 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

This study's planned enrollment of 500 is above the median of 147 across 756 interventional studies indexed under Hepatitis B.

Browse Hepatitis B studies →

Lead sponsor

University Hospital, Rouen is the lead sponsor of 418 studies on the registry; 106 are open to participants now.

Browse University Hospital, Rouen studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Former or active intravenous and/or nasal drug user
  • Person on opiate substitution therapy

Exclusion criteria

Exclusion Criteria:

  • Person with known active viral infection(s)
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Drug user

    Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection

    Diagnostic Test: Blood collection using Dried Blood Spot

Interventions

  • Diagnostic testBlood collection using Dried Blood Spot

    Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection

06

What researchers measure

Primary outcomes

  1. Number of person with an active hepatitis C infection

    Time frame: Day 1

  2. Number of person with an active hepatitis B infection

    Time frame: Day 1

  3. Number of person with an active AIDS infection

    Time frame: Day 1

07

Study locations

11 of 11 sites recruiting
  • Caarud Sud Manche
    Avranches, 50300, France
    Recruiting
    • Laure Perrot, Dr · Contactlaure.perrot@addictions-france.org
    • Laure Perrot, Dr · Sub investigator
    • Sophie Dubuche, Dr · Sub investigator
    • Rado Andriamanéo, Dr · Sub investigator
    • Arnaud Verchery, Dr · Sub investigator
  • Csapa Barentin
    Barentin, 76360, France
    Recruiting
  • Oeuvre Normande Des Meres
    Dieppe, 76200, France
    Recruiting
  • Csapa Act
    Elbeuf, 76500, France
    Recruiting
  • Csapa Gisors
    Gisors, 27140, France
    Recruiting
  • Csapa Nautilia
    Le Havre, 76600, France
    Recruiting
  • Csapa Pont-Audemer
    Pont-Audemer, 27504, France
    Recruiting
  • Aides Region Normandie
    Rouen, 76000, France
    Recruiting
    • Julien Bord, Dr · Contactbordjulien76@gmail.com
    • Julien Bord, Dr · Sub investigator
    • Stéphane Bord, Dr · Sub investigator
  • Csapa-Caarud La Boussole
    Rouen, 76000, France
    Recruiting
    • Véronique Michel, Dr · Contactrouillech@wanadoo.fr · 02.35.89.12.02.
    • Véronique Michel, Dr · Sub investigator
  • Chu Rouen
    Rouen, 76031, France
    Recruiting
    • Ghassan Riachi, Dr · ContactGhassan.riachi@chu-rouen.fr · 0232888990
    • Ghassan Riachi, Dr · Principal investigator
    • Alexandre Baguet, Dr · Sub investigator
    • Jean-Christophe Plantier, Pr · Sub investigator
    • Véronique Lemee, Dr · Sub investigator
  • Csapa Caux Et Bray
    Yvetot, 76190, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05390424
Lead sponsor
University Hospital, Rouen
Responsible party
Sponsor
First posted
May 25, 2022
Start date
Dec 2, 2022
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Ghassan RIACHI, MD
Contact
ghassan.riachi@chu-rouen.fr
+3323288 ext. 8265
Julien BLOT
Contact
julien.blot@chu-rouen.fr
+3323288 ext. 8265
Ghassan RIACHI, MD
principal investigator · University Hospital, Rouen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hepatitis B →

Other studies from this sponsor

University Hospital, Rouen →

Start the discussion